All In Biotech

Drug Trial Radar · NCT07034209

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))

An Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))

Last checked: Nov 19, 2026Latest source record: Jun 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Apr 7, 2023

Primary completion

Apr 18, 2025

Study completion Apr 18, 2025

Sponsor

Lead sponsor
TJ Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 16 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study adopts an open-label, single-arm, multicenter design to evaluate the efficacy, safety, tolerability, immunogenicity, and PK characteristics of Plonmarlimab administration in patients with rheumatic and immunological disease-associated HLH (MAS), and to explore biomarkers related to the efficacy of Plonmarlimab.

Conditions

  • Hemophagocytic Lymphohistiocytoses

Interventions

  • PlonmarlimabDrug

    Subjects receive Plonmarlimab 6 mg/kg or 10 mg/kg, administered intravenously, once weekly for 8 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate,ORRTime frame: At the end of Week 8

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Peking Union Medical College Hospital

    Beijing, China

  • Beijing Peking University People's Hospital

    Beijing, China

  • The First Affiliated Hospital of Nanjing Medical University

    Nanjing, China

  • Ruijin Hospital Of Shanghai Jiao tong University School of Medicine

    Shanghai, China

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Renji Hospital of Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.